|
Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Novartis; Novartis; Syndax |
Patents, Royalties, Other Intellectual Property - mercator therapeutics |
|
|
No Relationships to Disclose |
|
|
Research Funding - Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Taiho Pharmaceutical; Taiho Pharmaceutical |
|
Hussein Abdul-Hassan Tawbi |
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Merck; Novartis |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis |
Speakers' Bureau - Array BioPharma |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Lilly |
|
|
Honoraria - Monteris Medical; Novocure |
Research Funding - BMS (Inst); Medtronic (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Apexigen; Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; NanoString Technologies; Novartis; Sanofi; Syndax; Vaccinex |
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |